CardioGen-82 Cardiac Perfusion imaging is known and recognized
as a powerful tool in the assessment of coronary artery disease
(CAD). The high sensitivity, specificity and accuracy of cardiac
perfusion imaging can potentially reduce the costs associated with
CAD by decreasing the need for more expensive and higher risk,
invasive procedures.
CardioGen-82 is the only FDA-approved generator-based perfusion
agent reimbursed for the evaluation of coronary artery disease.*
IBA molecular’s unit dose program enables imaging facilities to
provide CardioGen-82 Cardiac Perfusion service to the community
by eliminating the cost requirement of a full-time CardioGen
generator.
For more information, please contact the sales representative in
your country.
*http://www.cardiogen.com/pages/cases.htm
